Analyst upgrades for Gilead and Intel follow strong earnings and a $15 billion capital raise, while AMD and Arista face near-term headwinds.
ALLKA Research upgraded Gilead Sciences (GILD) to Buy after Q2 results surpassed expectations, driven by robust sales in its HIV franchise and newer products. The company also raised its sales guidance, signaling confidence in growth momentum.
Intel (INTC) received an upgrade based on a $15 billion equity raise, which strengthened its balance sheet and supported AI initiatives. Analysts cited improved valuation and long-term potential as key factors. Meanwhile, AMD was downgraded due to margin pressures and a lack of near-term catalysts, while Arista Networks faced concerns over high valuations and peaking capital expenditure growth.